Research programme: complement system protein inhibitors - BMS

Drug Profile

Research programme: complement system protein inhibitors - BMS

Latest Information Update: 23 Jan 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator iPierian
  • Developer Bristol-Myers Squibb; iPierian
  • Class Monoclonal antibodies
  • Mechanism of Action Complement C1s inhibitors; Complement system protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune haemolytic anaemia; Cardiovascular disorders; Immunological disorders; Metabolic disorders; Neurodegenerative disorders

Most Recent Events

  • 08 Dec 2015 Discontinued - Preclinical for Autoimmune haemolytic anaemia in USA (Parenteral)
  • 08 Dec 2015 Discontinued - Preclinical for Immunological disorders in USA (Parenteral)
  • 29 Apr 2014 iPierian has been acquired by Bristol-Myers Squibb
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top